Benefits of Combining Metacognitive Training (MCT) With Cognitive Remediation (CR) in the Recovery of Patients With Psychotic Spectrum Disorders (CR+MCTp)

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to compare the efficacy of combined REHACOP + MCT alone in persons with nonaffective psychotic disorder in terms of recovery. The main questions it aims to answer are: * Does combined REHACOP + MCT therapy increase the clinical recovery in persons with nonaffective psychotic disorder (compared to MCT alone)? * What is the impact of combined REHACOP + MCT therapy compared to MCT therapy alone on personal/psychological recovery, cognitive biases, and social cognition, taking gender differences into account? * What is the durability of the effects of combined REHACOP + MCT therapy compared to MCT therapy alone on clinical recovery, personal recovery, cognitive biases, and social cognition in the long term? Researchers will compare REHACOP+MCT therapy to MCT alone to see if there are differences in personal/psychological recovery. Participants will: * Participate in Metacognitive Training or in combined REHACOP + Metacognitive training therapy. * Do 8 weekly sessions of 45-60 minutes (MCT group). * Do 12 weekly sessions of 45-60 minutes (RECHACOP+MCT group). * Visit the clinic for checkups and tests. * Answer self-administered tests.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Maximum Age: 55
Healthy Volunteers: f
View:

• Presence of one of the e following diagnostics according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5): schizophrenia, schizophreniform disorder, delusional disorder, brief psychotic disorder, schizoaffective disorder, and non specified schizophrenia spectrum disorder and other psychotic disorders.

• Be in a stable clinical phase (without psychiatric hospitalization in the last 3 months).

• Have good adherence to pharmacological treatment.

• T-score \< 40 in any cognitive outcome measured by TAVEC, CPT-IP, TMT, Stroop, WSCT, FAS and WAIS (Vocabulary, Digit Forward, Digit Backwards and Digit Symbol Coding.

• Willing to participate in the study expressed by providing signed informed consent.

Locations
Other Locations
Spain
Universitat Autonoma de Barcelona
RECRUITING
Cerdanyola Del Vallès
Contact Information
Primary
Ana Barajas Velez
ana.barajas@uab.cat
+34935814452
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 160
Treatments
Experimental: REHACOP+MCT therapy
The participants will receive a combined therapy: Metacognitive Training (MCT) with Cognitive Remediation (CR).
Active_comparator: MCT alone
The participants will receive Metacognitive Training (MCT)
Related Therapeutic Areas
Sponsors
Collaborators: Hospital de Mataró, Fundació Els 3 Turons, Centre d'Higiene Mental Les Corts, Consorci Sanitari de Terrassa, Hospital Son Espases, Hospital San Carlos, Madrid, Ministerio de Ciencia, Innovación y Universidades, Institut d'Assistència Sanitària, Parc Sanitari Sant Joan de Déu, Parc Taulí Hospital Universitari, Servicio Cántabro de Salud, Andaluz Health Service
Leads: Universitat Autonoma de Barcelona

This content was sourced from clinicaltrials.gov